Status:
COMPLETED
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
Lead Sponsor:
ContraVir Pharmaceuticals, Inc.
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is a Phase 1 study to evaluate the PK profile of TXL oral formulations in healthy subjects
Detailed Description
This is a Phase 1 study to evaluate the PK profile of different oral formulations of TXL following single dose administration in healthy subjects.
Eligibility Criteria
Inclusion
- Age:18-55 Capable of giving written informed consent Capable of completing study requirements
Exclusion
- History or medical condition which could impact patient safety History of drug or alcohol abuse within past 2 years Positive result for HIV, HBV, or HCV Participation in another clinical trial within the past 90 days
Key Trial Info
Start Date :
September 6 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 16 2018
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT03279146
Start Date
September 6 2017
End Date
June 16 2018
Last Update
August 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Quotient Clinical
Nottingham, United Kingdom